The Extracellular NADome Modulates Immune Responses by Audrito, V.


















Sciences, University of Turin,
Turin, Italy
Specialty section:
This article was submitted to
Cytokines and Soluble
Mediators in Immunity,
a section of the journal
Frontiers in Immunology
Received: 03 May 2021
Accepted: 21 July 2021
Published: 04 August 2021
Citation:
Audrito V, Messana VG,






published: 04 August 2021
doi: 10.3389/fimmu.2021.704779The Extracellular NADome
Modulates Immune Responses
Valentina Audrito†, Vincenzo Gianluca Messana, Lorenzo Brandimarte and Silvia Deaglio*
Laboratory of Cancer Immunogenetics, Department of Medical Sciences, University of Turin, Turin, Italy
The term NADome refers to the intricate network of intracellular and extracellular enzymes
that regulate the synthesis or degradation of nicotinamide adenine dinucleotide (NAD) and
to the receptors that engage it. Traditionally, NAD was linked to intracellular energy
production through shuffling electrons between oxidized and reduced forms. However,
recent data indicate that NAD, along with its biosynthetic and degrading enzymes, has a
life outside of cells, possibly linked to immuno-modulating non-enzymatic activities.
Extracellular NAD can engage puriginergic receptors triggering an inflammatory
response, similar - to a certain extent – to what described for adenosine triphosphate
(ATP). Likewise, NAD biosynthetic and degrading enzymes have been amply reported in
the extracellular space, where they possess both enzymatic and non-enzymatic functions.
Modulation of these enzymes has been described in several acute and chronic conditions,
including obesity, cancer, inflammatory bowel diseases and sepsis. In this review, the role
of the extracellular NADome will be discussed, focusing on its proposed role in
immunomodulation, together with the different strategies for its targeting and their
potential therapeutic impact.
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FACTOR TO DANGER SIGNAL
NAD is an essential intracellular metabolite with key roles in energy metabolism and electron
transfer (1–7). In addition, NAD is a cofactor for different families of enzymes, including sirtuins
and poly-ADP-ribosyl polymerases (PARPs). NAD can be present outside of cells, with levels
fluctuating widely in response to extracellular signals (8–11). A firm observation is that under steady
state extracellular (e)NAD levels are thousands of times lower (nM) compared to the intracellular
ones (µM-mM) (7, 12–16).
However, during conditions of cellular stress, such as those observed in an inflamed
microenvironment, or during hypoxia, or in conditions of shear stress due to physical distortion,
plasma membrane damage, stress elicited by cytotoxic agents, NAD concentrations may rapidly
spike. This observation, together with the finding that some purinergic receptors are activated by
NAD suggested that eNAD serves as a “danger signal” that alerts the immune system to tissue
damage (8–10, 12, 17–20). According to this view, eNAD could be considered as damage-associated
molecular pattern molecule (DAMP), able to activate the innate immune system, like what has beenorg August 2021 | Volume 12 | Article 7047791
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21–24). For example, released eNAD from active neuronal cells
can serve as neurotransmitter and neuromodulator (25–27); or
in a mouse model of inflammation, induced by injection of
polyacrylamide beads, eNAD reached a concentration of 10mM
acting as danger signal (28).
NAD release may occur by several mechanisms involving
active exocytosis, or diffusion through transmembrane
transporters (e.g., pannexin, connexin) in living cells, or
passive leakage across the membrane from necrotic or injured
cells (15, 29–32).
Homeostasis is rapidly restored through a scavenging circuit
operated by nucleotide-catabolizing enzymes that produce the
immunosuppressant adenosine (ADO) and inosine, which can
re-enter the cell, reconstituting the nucleotide pool (5, 33–36).
All these mechanisms of nucleotide/nucleoside release to alert or
switch off the immune system, respectively, are enhanced during
acute and chronic inflammation, including cancer (29, 37, 38).
Even though very unlikely, eNAD synthesis has not been
conclusively ruled out, also in consideration of the presence of
several key NAD biosynthetic enzymes (NBEs) (16, 39).Frontiers in Immunology | www.frontiersin.org 2INTRACELLULAR AND EXTRACELLULAR
NAD-METABOLIZING MACHINERY
The biosynthesis of NAD takes place in different locations in the
cell, through one de novo pathway starting from the catabolism
of tryptophan, and via degradation of vitamin B3 precursors. The
latter is considered a salvage pathway that occurs through the
metabolism of three precursors [i.e. nicotinic acid (Na),
nicotinamide (Nam) and nicotinamide riboside (NR)]. In the
majority of tissues, intracellular NAD is generated mostly from
Nam, which is the degradation product of all NAD-consuming
signaling reactions (6, 40–42). Under normal conditions >70% of
the cellular NAD content is stored and is utilized in the
mitochondria primarily for metabolic purposes (16, 43). The
cytosolic and nuclear NAD pools serve primarily to sustain
activity of PARPs and sirtuins, which are NAD-dependent
enzymes with key roles in regulating DNA repair and
epigenetic controlling of gene transcription, respectively
(Figure 1) (7, 44, 45). NAD levels can therefore restrict the
activity of these two classes of NAD-metabolizing enzymes.
Intriguingly, NAD can rapidly shuttle between different cellularFIGURE 1 | Schematic representation of the NADome. Schematic representation of the network of substrates/ligands, NAD-metabolizing cell surface and
intracellular enzymes and their products in the extracellular and intracellular space. Biological functions regulated by NAD-related enzymes and products are listed.
NAD, nicotinamide adenine dinucleotide; NADP, NAD phosphate; eNAD, extracellular NAD; Nam, nicotinamide; NR, nicotinamide riboside; Na, nicotinic acid;
NAMPT, nicotinamide phosphoribosyltransferase; NAPRT, nicotinate phosphoribosyltransferase; NRK, nicotinamide riboside kinase; ARTs, mono adenosine
diphosphate (ADP)-ribose transferases; PARPs, poly ADP-ribose polymerases; ADPR, ADP ribose; cADPR, cyclic ADP ribose; NAADP, nicotinic acid adenine
dinucleotide phosphate; Ca2+, calcium; NMN, nicotinamide mononucleotide; ADO, adenosine; AMP, adenosine monophosphate; ENPP1; ectonucleotide
pyrophosphatase/phosphodiesterases; TLR4, toll-like receptor 4.August 2021 | Volume 12 | Article 704779
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activation, as has recently been shown (46). When in the
extracellular space, eNAD functions are linked to the
modulation of cell surface P2X and P2Y purinergic receptor
families, thereby acting in an apparently enzyme-independent
way and eliciting pro-inflammatory immune responses
(Figure 1). In addition, within the extracellular space, a
complete network of different ectonucleotidases can rapidly
hydrolyze eNAD generating intermediates that modulate
signaling, cell metabolism, adhesion, migration and activate
immunoregulatory circuits (14, 39, 47), as summarized in
Figure 1 . eNAD is degraded by different classes of
ectoenzymes: the NADases CD38 and CD157 (48–50), the
ADP-ribosyltransferases (ARTs) (51), the Ectonucleotide
Pyrophosphatase/Phosphodiesterase 1 (ENPP1) and the ecto-
5′-nucleotidase CD73 (34, 52, 53). NADase, ENPP1 and CD73
can lead to the formation of ADO, a potent natural
immunosuppressive factor mediating the activation of the
inhibitory P1 purinergic receptors (34, 54, 55). In addition,
eNAD can be cleaved to nicotinamide mononucleotide (NMN)
and subsequently dephosphorylated to NR by CD38 and CD73
(53, 56, 57). All these intermediates can enter the cell as NAD
precursors and can be used by NBEs, reconstituting the
intracellular pool (57, 58) (Figure 1).
In the next sections of this review, we will summarize the role
of eNAD, its derived-metabolites and a set of NAD-dependent
enzymes, giving examples of their role in the regulation of
specific immune responses.eNAD AND PURINERGIC RECEPTORS
The idea of purinergic signaling, i.e., of nucleotides acting as
extracellular signaling molecules, was initially put forward by the
seminal work of Geoff Burnstock in 1972 (59, 60).
Since then, this complex network of receptors has
progressively been unveiled to reveal seven evolutionarily
conserved subtypes of the P2X ion channel receptors and eight
subtypes of the P2Y G protein-coupled receptor, all with roles in
immune cell activation (5, 24, 61). On the contrary, four subtypes
of the ADO P1 receptors on effector T cel ls have
immunosuppressive effects. Shifting the balance from pro-
inflammatory P2R signaling to anti-inflammatory P1R
signaling or vice versa, the purinergic signaling system fine-
tunes immune cell functions (5). eNAD can bind different
subtypes of purinergic P2 receptors as summarized in Figure 2.
For example, eNAD activates human granulocytes by binding
P2Y11 and triggering: (i) overproduction of cyclic (c)AMP,
(ii) activation of protein kinase A, (iii) stimulation of ADP-
ribosyl cyclase and overproduction of cyclic ADP-ribose
(cADPR), a universal calcium (Ca2+) mobilizer, and (iv) influx
of extracellular Ca2+, ultimately causing increased proliferation
and migration (62). eNAD can bind P2Y1 and P2Y11 in human
monocytes activated with lipopolysaccharide (LPS), triggering a
transient rise in intracellular Ca2+, which is caused by a release of
Ca2+ from IP (3)-responsive intracellular stores and an influx of
extracellular Ca2+ (63). eNAD has also been identified as anFrontiers in Immunology | www.frontiersin.org 3agonist at P2Y1 receptors in human embryonic kidney (HEK)
cells and mouse colonic muscle (27, 64). Moreover, binding to
postsynaptic P2Y1 receptors, like ATP, eNAD also acts as a
neurotransmitter, released by stimulated terminals of
mammalian central nervous system and peripheral nervous
system neurons (65). In addition, it has been shown that
purinoceptors, including P2X1, P2X4, and P2X7, are engaged
in eNAD-mediated signaling (27, 63, 66). However, more
experimental data should be published to confirm this direct
binding of NAD per se.
eNAD may also engage P2X7R receptors, the main eATP
receptor, extensively studied in the context of inflammation and
immunity (24). P2X7R signaling is a major regulator of the
intensity and duration of inflammatory responses (24, 67, 68).
The receptor/channel is prominently expressed on all cells of
innate and adaptive immunity and aberrant signaling has been
linked to diverse inflammatory and autoimmune diseases, as
recently reviewed in (5, 24). P2X7R signaling mediates NLR
family pyrin domain containing 3 (NLRP3) inflammasome
activation, cytokine, and chemokine release [i.e., interleukin
(IL)-1b, tumor necrosis factor (TNF), IL-6, monocyte
chemoattractant protein-1 (MCP-1/CCL2)], T lymphocyte
survival and differentiation, transcription factor activation, and
cell death (24, 69, 70). At inflammatory sites, P2X7R could also
be bound directly by alternative ligands, including eNAD that
accumulates at sites of inflammation and tissue damage (28). In
murine T lymphocytes, eNAD serves as an ADP-ribose donor to
ADP-ribosylate the P2X7R at arginine 125, close to the ATP-
binding pocket (71). This reaction, catalyzed by the plasma
membrane enzyme ART2.2, causes long-lasting activation of
mouse P2X7R, negatively affecting T-regulatory (Treg) and
natural killer T (NKT) cell survival and arguing in favor of a
direct role of eNAD in the pathophysiological mechanism of
P2X7R activation. The reduction of Treg function via NAD-
induced gating of P2X7 can be employed in vivo as a strategy to
promote the antitumor response of effector T cells. Systemic
injection of NAD results in the selective depletion of Tregs via
NAD-mediated activation of P2X7, which enhances anticancer
immune responses in several mouse tumor models (20, 72).
While highly interesting and potentially relevant for human
immune responses, this mechanism of P2X7R activation via
eNAD is demonstrated only in mouse models: additional
research is needed to determine whether it is relevant for
human immune responses too.eNAD DEGRADATION-SIGNALING
SYSTEM IN REGULATING IMMUNE
RESPONSES
One of the reasons why eNAD levels are generally low is that
there are several extracellular enzymes that rapidly transform it,
guaranteeing recycling of a high energy molecule through the
generation of products that can be easily up-taken by cells. The
intermediates, however, have a life of their own as signaling
molecules, thereby modulating activity of immune cells.August 2021 | Volume 12 | Article 704779
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activity of CD38, an immunomodulatory enzyme (Figure 3).
Human CD38, the main member of the NADase/ADPR
cyclase family that includes also CD157/BST-1, is a surface
glycoprotein characterized by a relatively large extracellular
domain that contains the catalytic site, a single transmembrane
pass, and a short cytoplasmic tail (73, 74). CD38 is a
multifunctional ectoenzyme, involved in the catabolism and
degradation of eNAD (under normal pH) and NAD phosphate
(NADP, under acidic pH), producing ADP ribose (ADPR)
together with signaling metabolites involved in intracellular
Ca2+ mobilization. The main catalytic activity is the NAD
glycohydrolase that generates Nam and ADPR. CD38 can also
act as NAD cyclase, producing cADPR, which is then hydrolyzed
to ADPR. Lastly, in the presence of NADP and Na, under acidic
pH levels, CD38 can generate nicotinic acid adenine dinucleotide
phosphate (NAADP) (49). The finding of an extracellular
enzymatic activity of CD38 leading to the generation ofFrontiers in Immunology | www.frontiersin.org 4messengers that enter cells to induce intracellular Ca2+ fluxes
remains an unsolved “topological paradox” (49, 75). More recent
data have enriched the picture by showing that CD38 can also be
found in the nucleus and mitochondrial membrane and that a
soluble form of CD38 is most likely present in the cytoplasm,
leading to the hypothesis of a compartmentalized generation of
NAD-derived signaling metabolites (49, 76–78). ADPR, cADPR
and NAADP share the ability to mobilize Ca2+ ions from
intracellular stores: cADPR binds to ryanodine receptors (RyR)
expressed on the endoplasmic reticulum, ADPR binds to
membrane melastatin related transient receptor potential
cation channels TRPM2 (49, 79) and NAADP binds to
receptors expressed by acidic organelles, such as lysosomes,
suggesting a role as Ca2+ messenger in the endocytic pathway
(80). It is therefore likely that during an immune response, NAD,
released outside of cells due to local conditions of inflammation
and cellular damage is converted into Ca2+-active metabolites
through the action of CD38 expressed by activated lymphocytes,FIGURE 2 | eNAD and purinergic signaling. Pathological or physiological stimuli, including hypoxic and inflammatory conditions, metabolic and cellular stress,
promote the release of NAD from the cell. NAD can then bind to P2X (isoforms P2X1, P2X4, P2X7) and P2Y (isoforms P2Y1, P2Y11), activating several intracellular
signaling and modulating immune responses.August 2021 | Volume 12 | Article 704779
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signaling (80–82).
There is a second alternative possibility that is gaining
momentum in the context of tumor immunosuppression.
According to this hypothesis, ADPR could also be short-
circuited to ADO via the action of CD203, which generates
AMP from ADPR and CD73 (53, 83, 84), which cleaves the last
phosphate, generating ADO (49). In this way, CD38 could
contribute to the generation of a tumor-favorable environment,
as recently demonstrated in tumors characterized by a large T
cell infiltrate (85). Therefore, it seems that according to the
environment, CD38 can generate both immune-boosting and
immune-suppressive metabolites, thereby activating or
suppressing immune responses.
These at times opposing roles of CD38 in defining immune
responses are in part confirmed by studies on CD38-deficient
mice. Interestingly, when the animals are kept in clean facilities
without infectious challenges, they grow and develop normally,
without major defects (86). On the other hand, during infections
they show impaired lymphocyte activation and homing and are
ultimately more susceptible to death due to sepsis (87, 88). CD38-Frontiers in Immunology | www.frontiersin.org 5deficient animals also show reduced tumor formation, attributed
to the lack CD38-mediated immunosuppression.
In the human system, CD38 is widely expressed on the
surface of immune cells, particularly in conditions of cellular
activation. On the cell surface, CD38 is part of the
immunological synapse, forming lateral associations with
critical receptors on T, B, and myeloid cells, thereby
positioning itself at the center of action (48, 49). In fact, it was
reported that CD38 localizes in close contact with T cell receptor
(TCR), the B cell receptor (BCR), and key chemokine receptors,
among other molecules (89). Perhaps the best understood
function of CD38 is in the regulation of T lymphocyte
functions, where the enzyme works again different ways (90–93).
First, CD38-dependent-Ca2+ signaling directly contributes to
T cell activation, likely providing an essential second signal that
drives gene expression and consequently differentiation,
development, and cytotoxicity (93–95).
As a second level of T cell regulation, the NAD/CD38 axis was
proposed to control T cell metabolic reprogramming needed for
full T lymphocyte activation through the modulation of sirtuin
activity (90, 96). Several studies are shedding light on thisFIGURE 3 | eNAD and enzymatic/functional extracellular machinery in regulating immune responses. Extracellular NAD can also be metabolized by a series of
enzymes of the cell surface that are involved in scavenging of nucleotides. The end product of the reaction, adenosine, can then be internalized and reconverted to
related nucleosides (e.g., ATP or NAD). In particular, CD38 hydrolyzes NAD to generate intermediates (cADPR and ADPR), potent intracellular Ca2+-mobilizing
agents, through binding RyR or TRPM2 receptors. CD38 activation induces migration, proliferation, and modulation of immune responses, specifically T cell
functions, as detailed in the text. In addition, CD38 activity releases nicotinamide (the main NAD precursor) that can be internalized into the cell and, together with a
second precursor nicotinic acid, converted in NAD by NAMPT and NAPRT activities, respectively, increasing intracellular NAD levels and affecting sirtuins and PARPs
(NAD-consuming enzymes) functions. NAMPT and NAPRT can be secreted/released in the extracellular space acting as cytokine-like proteins. Finally, NAD and ATP
can be converted in adenosine. ATP is metabolized by CD39 to AMP that is further hydrolyzed by ecto-5’-nucleotidase/CD73 which promotes the formation of
adenosine. Adenosine then activates adenosine receptors (purinergic receptor P1). The final outcome depends on the relative concentrations of substrates and
products and on the expression of nucleotide-metabolizing ecto-enzymes and NAD-biosynthetic enzymes. NAD, nicotinamide adenine dinucleotide; NADP, NAD
phosphate; NAMPT, nicotinamide phosphoribosyltransferase; NAPRT, nicotinate phosphoribosyltransferase; PARPs, poly ADP-ribose polymerases; ADPR, ADP
ribose; cADPR, cyclic ADP ribose; NAADP, nicotinic acid adenine dinucleotide phosphate; ATP, adenosine triphosphate; AMP, adenosine monophosphate; P1,
adenosine purinergic receptor; RYR, ryanodine receptors; TRPM2, transient receptor potential melastatin-related 2; i, intracellular; e, extracellular.August 2021 | Volume 12 | Article 704779
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contributing to several aspects of cellular energy metabolisms,
including glycolysis, oxidative phosphorylation (OXPHOS),
glutaminolysis, which are strictly associated with T cell
functional fate (90, 93, 97, 98). According to the models
proposed, expression of CD38 on the cell surface would limit
intracellular NAD levels, negatively impacting on the activities of
the NAD-dependent enzymes SIRT1 and SIRT3, which are
deacetylases with fundamental roles in epigenetic regulation
(93). Lastly, recent data indicate that CD38 is highly expressed
by specific subsets of immunosuppressive tumor infiltrating
lymphocytes, including regulatory T cells and T helper 17 cells
(90, 99–101). Expression of the molecule occurs often in
association with exhaustion markers, such as programmed cell
death protein 1 (PD-1), pointing to an active role of CD38 in
modulating T cell fate toward the generation of an immune
tolerant landscape in tumors, likely through the generation of
ADO (90) (Figure 3).
What remains unclear so far is what are the factors that tip the
balance in favor of Ca2+-active metabolites and hence immune
activation or in favor of ADO and hence immunosuppression (93,
94, 102–104). Therefore, inhibition of CD38 is a valid therapeutic
strategy to reestablish a functional immune surveillance (105),
open the way to combination therapies with immune checkpoint
inhibitors, as discussed in a separate paragraph.eNAD BIOSYNTHETIC-SIGNALING
SYSTEM IN REGULATING IMMUNE
RESPONSES
Beside NAD-consuming, also NBEs were reported in the
extracellular compartment. The best known and characterized
among them is nicotidamide phosphoribosyltransferase
(NAMPT), which catalyzes the conversion of Nam to NMN in
the presence of phosphoribosyl pyrophosphate (PRPP) and ATP
(7, 44).
The presence of NAMPT in biological fluids is now well
established: however, several years were needed before realizing
that a cytokine promoting B cell differentiation and originally
described in mid-nineties (106), and an extracellular adipokine
called visfatin were in fact the same protein as NAMPT (11, 107,
108). Of note, different cell types, including neutrophils,
monocytes, macrophages, and cancer cells secrete eNAMPT in
the extracellular space in response to inflammation, cellular
stress, infections, and hypoxic conditions, among others. In
human plasma eNAMPT normal levels are in the low
nanomolar range (2-4 ng/ml), but it is over-expressed in
several inflammatory and metabolic disorders, including
cancer, where concentrations can increase 10-20 times (11, 108).
The second NBE dosed in biological fluids is nicotinic acid
phosphoribosyltransferase (NAPRT), which controls the NAD
generation pathway starting from Na. While the NAMPT
pathway is probably the predominant one in most cells and
tissues, considering that all NAD-consuming enzymes generate
Nam, the activity of NAPRT is believed to boost NAD levels inFrontiers in Immunology | www.frontiersin.org 6stress conditions (44, 109–111). Information on eNAPRT is far
more limited, even though concentration data indicate again a
physiological level in low nanomolar range (1-2 ng/ml), raising
sometimes dramatically, particularly during sepsis (112).
Whether these enzymes are active in the extracellular
compartment remains uncertain, mainly because of the
absence of detectable PRPP levels, an essential co-factor to
produce NMN and nicotinic acid mononucleotide (NaMN). In
addition, the rest of the enzymatic cascade producing NAD has
never been reported in the extracellular space (109). From data
present in the literature, we can exclude a direct eNAD synthesis
in physiological conditions, but we cannot exclude a site-specific
and transient eNAD synthesis in inflammatory conditions, due
to release of intracellular molecules (ATP, PRPP) and enzymes.
In favor of a compartment-specific function, the active forms
of these enzymes are in a dimeric conformation, but within the
extracellular compartment they should be in a monomeric,
and hence inactive, form (113). Lastly, functional studies have
shown that eNAMPT and eNAPRT, genetically modified to be
enzymatically inactive, retain their pro-inflammatory properties
(112) (Figure 3).
A second area of investigation concerns the mechanisms of
trafficking of these enzymes from the intracellular to the
extracellular space, which appear “non-classical”, as secretion is
unaffected by monensin and brefeldin A, two inhibitors of the
classical endoplasmatic reticulum (ER)–Golgi secretory pathway
(114–117). An interesting finding indicates that NAMPT secretion
could be regulated through SIRT1- and SIRT6-deacetylation,
thereby linking NAD-biosynthetic and -consuming enzymes, and
potentially suggesting eNAMPT secretion as regulatory mechanism
to decrease its intracellular concentrations (118, 119). Recent
evidence showed that eNAMPT is carried in extracellular vesicles
(EVs) through systemic circulation in mice and humans. EV-
contained-eNAMPT is internalized into cells, enhancing NMN
and hence NAD synthesis (120). eNAMPT is actively secreted via
exosomes also from microglia during neuroinflammation due to
ischemic injury (121). These findings support the possibility of
metabolic exchange between tumor/inflammatory and immune
cells and vice versa within the site of inflammation or the tumor
microenvironment (TME), as previously described for other
cytokines and metabolic molecules (122, 123).
The conclusion from these data is that outside of cells it is
unlikely that NAMPT and NAPRT function as NAD-producing
enzymes, raising the alternative possibility that they possess
different functions. In fact, eNAMPT can directly bind Toll-
like receptor 4 (TLR4) (112, 124) and C–C chemokine receptor
type 5 (CCR5) (125), which might explain how the protein is
involved in the activation of an inflammatory signature. The
binding with TLR4 was demonstrated in different cellular
models, leading to activation of specific intracellular signaling
pathways (e.g., STAT3, NF-kB, Akt, P38) within minutes, and
activation of inflammasome in few hours (112, 124).
Less recently, it was reported that eNAMPT can selectively
inhibit infection of monocytes by human immunodeficiency
virus (HIV) and this activity was linked to a direct interaction
with CCR5, shown using surface plasmon resonance (SPR)
(126). More recently, Torretta et al. suggested that eNAMPTAugust 2021 | Volume 12 | Article 704779
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the cancer microenvironment, eNAMPT seems to contribute to
shape an immunotolerant environment, mostly acting on the
myeloid component. We described a role for eNAMPT in the
differentiation of circulating monocytes from chronic
lymphocytic leukemia (CLL) patients toward tumor-supporting
M2 macrophages (127). Recently, it was demonstrated that
iNAMPT acts also on myeloid-derived suppressor cells
(MDSCs) via a SIRT1/hypoxia-inducible factor (HIF)-1a axis,
promoting their mobilization (128). The activation of these
circuits creates an immunosuppressive and tumor-promoting
microenvironment (Figure 3).
Much less is known on eNAPRT, even though from early
information it seems to possess properties similar to NAMPT
when in extracellular fluids. Managò et al. demonstrated that
eNAPRT binds TLR4 on macrophages triggering NF-kB
activation and pro-inflammatory cytokines secretion (112).
Moreover, eNAPRT shares with eNAMPT the activation of a
transcriptional program, maybe mediated by the induction of
macrophage colony-stimulating factor (M-CFS), to force
monocyte differentiation into macrophages. In turn,
macrophages are a source of eNAMPT and eNAPRT in vivo
(112). Even if several issues remain to be investigated, a
functional role of these enzymes in primary innate immunity
responses is clearly emerging, opening the way to target these
enzymes to modulate inflammation.IS THE NADome A THERAPEUTIC
TARGET?
Alterations in the NADome have been described in several
human diseases, including inflammatory conditions (gastricFrontiers in Immunology | www.frontiersin.org 7and intestinal inflammatory diseases, graft-versus-host disease,
sepsis and multiple organ failure, allergies particularly in the
lungs, atherosclerosis, age-associated insulin resistance,
neuroinflammation/degeneration), autoimmune diseases
(multiple sclerosis, psoriasis, systemic lupus erithematosous),
cardiovascular diseases and cancer (7, 55, 129).
In addition to their role in shaping the immune system and in
creating immunosuppressive conditions, in some instances
NAD-metabolizing enzymes are considered biological
prognostic markers and therapeutic targets. Among them, the
most promising are CD38, CD73 and NAMPT and the disease
setting is cancer (Figure 4).
CD38 is expressed in hematological malignancies, including
acute B lymphoblastic leukemia (B-ALL), acute myeloid
leukemia (AML), mantle cell lymphoma (MCL), CLL, multiple
myeloma (MM) and NK/T cell leukemia (T-ALL) (55, 94, 102,
105, 130–132). The role of CD38 has been widely explored and
defined in CLL and in MM. On CLL B lymphocytes, CD38
associates with the BCR complex [BCR/CD81/CD19/CD21] and
cooperates to amplify the signal transduction driving cell
proliferation (55, 133, 134).
Patients with CLL with a higher proportion of leukemic cells
expressing CD38 ≥30% experience a shorter time to first
treatment and a more aggressive clinical course with inferior
overall survival compared to patients who have <30% of CD38+
CLL cells, thus establishing surface CD38 as a marker of poor
prognosis (135–137).
MM is a plasma cell neoplastic aggressive disease with a median
overall survival of 4.4–7.1 years (138). CD38 is highly and
ubiquitously expressed on MM cells and at low levels on normal
lymphoid and myeloid cells (49, 139). Daratumumab is a first-in-
class anti-CD38 therapeutic monoclonal antibody (mAb) approved
in 2015 for the treatment of relapsed/refractory MM (140).FIGURE 4 | CD38, CD73 and NAMPT as markers and therapeutic targets in pathological conditions. CD38, CD73 and NAMPT expression levels increase in several
pathological conditions. These molecules become markers of aggressive disease. In the lower part of the cartoon specific pharmacological inhibitors and/or blocking
antibodies, currently in preclinical or clinical trials for each target are listed.August 2021 | Volume 12 | Article 704779
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dependent cell cytotoxicity (ADCC), complement dependent
cytotoxicity (CDC), antibody-dependent cellular phagocytosis
(ADCP), and inhibition of CD38 enzymatic activities and
induction of apoptosis in a caspase-dependent manner (132,
141, 142). This Ab is now used in combination with other
drugs; however, the density of CD38 molecules on MM cells is a
predictive factor to the efficacy and durability of daratumumab
treatment (143). In CLL, CD38 engagement by daratumumab
modulates BCR signaling and enhances the anti-CLL activity of
ibrutinib, an inhibitor of BCR signaling (144). In addition, CD38 is
highly expressed in different solid tumors (i.e., gliomas, pancreatic
cancer, non-small cell lung cancer, melanoma, hepatocellular
carcinoma), generally associated to increased aggressiveness and
creating a tumor-supportingmicroenvironment (145), providing a
rationale for the expansion of daratumumab’s field of action.
Targeting CD73 to interfere with the degradation of AMP
into ADO, reducing the generation of an immunosuppressed
and pro-angiogenic niche that promotes the onset and
progression of cancer, is an attractive therapeutic option (146).
CD73 expression is higher in the majority of human solid
tumors. Its expression and activity are closely associated with
tumor invasiveness and metastasis (147, 148).
Inhibition of CD73 using either mAb or small molecule
inhibitors such as a,b-methylene-ADP (APCP) have
demonstrated antitumor activities in preclinical tumor mouse
models (148, 149). Furthermore, a number of anti-CD73 mAbs
(MEDI9447, BMS986179, SRF373/NZV930, CPI-006/CPX-006,
IPH5301, TJ004309) and selective inhibitors (LY3475070,
AB680, CB-708) are being tested in early phase clinical trials,
as recently reviewed in (147, 150).
Therefore, combination therapies with CD73 blocking Abs or
small molecule inhibitors and other therapeutic strategies
including immune checkpoint blockade, adoptive T cell
therapy, agonistic immunotherapy, chemotherapy, and
radiation therapy, could have synergic effects in various
cancers boosting immune response to keep the tumor cells in
control, as emerged by recent studies (148, 151).
The first NAMPT inhibitor FK866 (also known as APO866)
was described in 2003 by Hasmann et al. (152) Since that, several
specific NAMPT inhibitors were developed as recently reviewed
in in (7, 153, 154). The rationale was mainly supported by the
over-expression of NAMPT in cancer cells, as extensively
described by us and by several research groups (11, 108, 117,
127, 155–158).
This led to a first wave of molecules that entered clinical trials
for cancer therapy; however, no molecules reported to have
progressed to later stages [www.clinicaltrials.gov (7, 153)].
Toxicity of old inhibitors and rescue mechanisms by the
activation of other NBEs following NAMPT block, have
limited the use of NAMPT inhibitors as single agents.
However, increasing evidence suggests that a better selection of
tumor subtype rely exclusively on NAMPT activity to generate
NAD, as well as novel drugs less toxic, could open a second life
for NAMPT inhibition strategy. Moreover, a combination
between NAMPT inhibitors and selective inhibitors ofFrontiers in Immunology | www.frontiersin.org 8oncogenic signaling driving cancer progression could be
therapeutically exploited as suggested (11, 117, 159).
An unknown notion is whether these inhibitors could also
affect eNAMPT activity, even if, as mentioned before, the
enzymatic activity of eNAMPT is controversial. Travelli et al.
developed novel inhibitors that can’t cross the plasma membrane
and have more activity to block eNAMPT form, demonstrating
reduced growth of triple negative mammary carcinoma in mice
(160). On the other hand, there is also intense research to
develop a blocking antibody to neutralize eNAMPT and reduce
its “cytokine-like activity” within the TME. The group of Garcia
firstly has devised a polyclonal eNAMPT neutralizing antibody
(pAb) (161). They used this Ab in different models of
inflammation and cancer, including lung injury and prostate
cancer. Recently, in acute respiratory distress syndrome (ARDS)
they demonstrated the highly significant contribution of
endothelial cell (EC)-derived NAMPT to the severity of
inflammatory lung injury in preclinical ARDS models.
Intravenous delivery of either eNAMPT-neutralizing pAb/mAb
significantly attenuated inflammatory lung injury in mouse
model. In vitro studies on EC demonstrated that eNAMPT-
neutralizing antibodies strongly abrogate eNAMPT-induced
TLR4 pathway activation (162). In invasive prostate cancer
(PCa) Sun et al. proved the activity of eNAMPT in supporting
the invasive features of PCa, and the tumor blocking activity of
the anti-eNAMPT neutralizing antibody in a pre-clinical in vivo
model of PCa invasion (163). In parallel, the group of Prof.
Genazzani in Italy is developing a novel monoclonal antibody
(C269) that neutralizes in vitro the cytokine-like action of
eNAMPT and that reduces its serum levels in rodents. This Ab
is able to significantly reduce acute and chronic colitis in two
models of induced-colitis (164), suggesting a role of eNAMPT
in the pathogenesis of inflammatory bowel disease (IBD) and
the therapeutic potential of its neutralization in this pathology.
The general idea of targeting eNAMPT in tumors and
in inflammatory diseases is increasing to counteract the
extracellular functions of this protein, mainly linked to the
activation of TLR4 and modulation of immune responses.
The best option could be to combine i/eNAMPT targeting with
immunomodulatory agents to obtain a tumor growth regression
and a concomitant reversion of immunosuppressive conditions,
acting on the immune system. In support of this, two papers
demonstrated that NAMPT inhibitors enhance the anti-tumor
efficacy of immune checkpoint inhibitors, i.e. antibody against
PD-1 (128, 165).CONCLUSIONS AND FUTURE
PERSPECTIVES
Since the discovery of the presence of extracellular nucleotides
such as ATP and NAD released from intracellular stores in
conditions of cell stress or inflammation, they are considered
“danger signals” to alert the immune system, participating in the
recruitment, activation, and differentiation of immune cells, and
promoting the production and release of pro-inflammatoryAugust 2021 | Volume 12 | Article 704779
Audrito et al. NAD-Metabolizing Enzymes in Immune Regulationcytokines. Within the TME, extracellular nucleotides create pro-
tumor conditions acting directly on tumor aggressive features but
also on immune cells promoting a general immunosuppression.
The extracellular machinery that regulates eNAD functions is
complex, as we summarized in this review several eNAD-
metabolizing enzymes rapidly degrade it into metabolites that in
turn can function as signaling messengers or can be internalized
and used to reconstitute the intracellular NAD pool. Directly,
eNAD can bind purinergic receptors and activate signaling. The
effects of eNAD are therefore dependent on the presence of
receptors, metabolizing enzymes and cellular stress conditions
within the microenvironment. Understanding this intricate
machinery remains the most important challenge to develop
therapeutic strategies to modulate expression of these extracellular
nucleotides, relative enzymes, and receptors to re-educate the
immune system in different diseases, including cancer.Frontiers in Immunology | www.frontiersin.org 9AUTHOR CONTRIBUTIONS
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